HanAll Biopharma kept up its sales growth last year, but annual operating profit swung to a loss due to higher selling, general and administrative costs.
HanAll Biopharma said on the 21st in a preliminary earnings filing that 2025 sales on a consolidation basis rose 11.7% from a year earlier to 155.285 billion won. Over the same period, it posted an operating loss of 916 million won, turning to a loss from a year earlier, when it recorded 230 million won in operating profit. Net loss came to 5.50588 billion won.
By quarter, fourth-quarter sales last year were 37.549 billion won, up 3.1% from a year earlier, but it turned to an operating loss of 2 billion won from a profit in the previous quarter. Fourth-quarter net loss was 6.248 billion won.
The company said profitability weakened due to higher selling, general and administrative expenses. It emphasized, however, that both top-line growth and clinical progress were achieved in the pharmaceuticals and new drug research and development areas.
Sales in the pharmaceuticals area were tallied at 133.8 billion won, up about 13% from a year earlier.
The probiotics drug "Biotop" established itself as a flagship product with annual sales of 23.8 billion won last year, and the hair loss treatment portfolio also surpassed 10 billion won in annual sales. The company said the finasteride hair loss treatment "Hairgrow" maintains the No. 1 share in the generic prescription and dispensing market. The prostate cancer and precocious puberty treatment "Eligard" is also sustaining stable sales in its market.
In research and development (R&D), clinical results continued for the autoimmune disease treatment pipeline. The FcRn therapy batoclimab met primary endpoints in phase 3 trials for myasthenia gravis (MG) and secured maintenance-effect data in phase 2 trials for Graves' disease (GD). The follow-up molecule imeroplubart (HL161ANS, IMVT-1402) has entered phase 2 or registrational stages in six indications.
HanAll Biopharma plans to launch eight new products this year and is set to announce clinical results for key new drug pipelines. These include two phase 3 trials of batoclimab for thyroid eye disease (TED), topline registrational results for imeroplubart in difficult-to-treat rheumatoid arthritis (D2T RA), and early clinical results in cutaneous lupus erythematosus (CLE), which will be released sequentially. Phase 3 results for the dry eye disease treatment tanfanercept and whether the Parkinson's disease treatment HL192 enters clinical trials are also cited as key variables this year.
A company official said, "It was a year in which stable sales growth in the pharmaceuticals area coincided with clinical progress in the new drug pipeline," adding, "This year will be a period when clinical results from key pipelines come out in earnest."